REUN — Reunion Neuroscience Income Statement
0.000.00%
Last trade - 00:00- $12.47m
- -$7.91m
- 10
- 41
- 28
- 15
Annual income statement for Reunion Neuroscience, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | C2021 March 31st | R2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.961 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | — | -1.09 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.255 | 0.241 | 22.2 | 17.9 | 34.3 |
| Operating Profit | -0.255 | -0.241 | -21.2 | -17.9 | -34.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.251 | -0.24 | -23.1 | -17.8 | -38.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.251 | -0.24 | -23.1 | -17.8 | -38.1 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -0.251 | -0.24 | -23.1 | -54.7 | -48.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.251 | -0.24 | -23.1 | -54.7 | -48.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.15 | -1.51 | -3.18 | -1.54 | -2.47 |